Recurrent Pericarditis Market By Treatment Type (NSAIDs, Colchicine, Corticosteroids, IL-1 Inhibitors, Immunosuppressants); By Disease Etiology (Idiopathic Recurrent Pericarditis, Autoimmune-Associated Recurrent Pericarditis, Post-Cardiac Injury Recurrent Pericarditis, Infectious Recurrent Pericarditis); By Route of Administration (Oral Administration, Subcutaneous Administration, Intravenous Administration); By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies); By End User (Hospitals, Specialty Clinics, Homecare Settings); By Geography (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), Segment Revenue Estimation, Forecast, 2026–2032

Recurrent Pericarditis Market: How Are Targeted Therapies Reshaping Recurrence Prevention and Treatment Spending? – (Updated On: 27th-Oct-2026)

Repeated inflammation around the heart is increasing the need for long-term medicines that control symptoms and prevent further episodes, creating opportunities for pharmaceutical companies developing targeted anti-inflammatory and biologic therapies. Strategic Market Research estimates the global recurrent pericarditis market at USD 694.94 million in 2025, with revenue projected to reach USD 1.83 billion by 2032. The anticipated 14.81% CAGR during 2026–2032 reflects expanding adoption of IL-1 inhibitors, increased treatment of patients with multiple recurrences, and growing use of specialized therapies for long-term disease management.

 

According to Kiniksa Pharmaceuticals' 2025 annual filing, approximately 40,000 patients receive treatment for recurrent pericarditis each year in the United States, including 14,000 patients with repeated or ongoing episodes and 26,000 experiencing their first recurrence. These estimates show the need for effective medicines that control inflammation and prevent the condition from returning.

 

Repeated episodes increase the need for long-term treatment. The 2025 European Society of Cardiology guidelines indicate that approximately 15–30% of patients experience another episode after initial acute pericarditis, while recurrence rates can reach 50% among patients who have already experienced a recurrence. These findings highlight the importance of treatments that prevent repeated inflammation around the heart.

 

Advanced treatment use is expanding in the United States. According to Kiniksa Pharmaceuticals' July 2026 update, approximately 21% of U.S. patients with multiple recurrences were receiving ARCALYST (rilonacept) by June 2026. More than 5,000 healthcare professionals had prescribed the medicine since its launch, showing increasing acceptance of specialized treatment for recurrent pericarditis.

 

Which Subsegments Are Leading the Recurrent Pericarditis Market and Emerging as Key Commercial Opportunities?

By Treatment Type: IL-1 Inhibitors Lead in Market Share and Expansion

IL-1 inhibitors lead the global Recurrent Pericarditis Market with a 36% share, accounting for USD 250.18 million in 2025, and are projected to register the fastest CAGR of 22.80% during 2026–2032. Their market leadership is supported by growing clinical adoption of targeted therapies that control IL-1-mediated inflammation and reduce recurrent episodes. IL-1 inhibitors are particularly valuable for patients experiencing inadequate responses to nonsteroidal anti-inflammatory drugs (NSAIDs), colchicine, or corticosteroids, strengthening their role in managing difficult-to-treat recurrent pericarditis and reducing corticosteroid dependence.

 

By Disease Etiology: Idiopathic Recurrent Pericarditis Leads in Both Market Share and Expansion

Idiopathic Recurrent Pericarditis holds the largest share of the global Recurrent Pericarditis Market at 58%, accounting for USD 403.07 million in 2025, and is projected to register the fastest CAGR of 15.50% during 2026–2032. Idiopathic cases represent over 80% of recurrent pericarditis cases in which no identifiable secondary cause, such as infection or systemic autoimmune disease, is established. The high prevalence of unexplained recurrent episodes, persistent inflammation, and repeated treatment requirements supports the growing adoption of targeted anti-inflammatory therapies, particularly IL-1 inhibitors.

 

By Route of Administration: Oral Therapies Lead While Subcutaneous Administration Expands Rapidly

Oral administration dominates the global Recurrent Pericarditis Market, accounting for a 56% market share, valued at USD 389.17 million in 2025, and is projected to grow at a CAGR of 9.60% during 2026–2032. Oral NSAIDs and colchicine remain central to first-line treatment, helping control inflammation and reduce recurrence risk, while oral corticosteroids serve as second-line options for selected patients. Established clinical guidelines, convenient dosing, and widespread availability of oral medications support their continued use in managing recurrent pericarditis across healthcare settings worldwide.

Subcutaneous administration is the fastest-growing category in the global Recurrent Pericarditis Market, accounting for a 39% market share, valued at USD 271.03 million in 2025, and is projected to grow at a CAGR of 21.00% during 2026–2032. Growth is supported by the increasing use of targeted biologic therapies, particularly interleukin-1 inhibitors, for managing recurrent or refractory pericarditis. Subcutaneous injections enable sustained control of inflammation, reduce recurrence risk, and provide an effective treatment option for patients who respond inadequately to conventional therapies.

 

By Distribution Channel: Specialty Pharmacies Lead in Market Share and Expansion

Specialty Pharmacies lead the global Recurrent Pericarditis Market with a 37% market share, valued at USD 257.13 million in 2025, and are projected to register the fastest CAGR of 20.50% during 2026–2032. Their market leadership is supported by the growing use of specialized biologic therapies, including interleukin-1 inhibitors, for managing recurrent inflammatory episodes. Specialty pharmacies facilitate access to high-cost prescription treatments, coordinate insurance approvals, provide medication counseling, and support long-term treatment adherence, strengthening their role in recurrent pericarditis management across healthcare systems.

 

By End User: Hospitals Lead While Homecare Settings Register the Fastest Expansion

Hospitals dominate the global Recurrent Pericarditis Market, accounting for the largest 48% market share, valued at USD 333.57 million in 2025, and are projected to expand at a CAGR of 12.50% during 2026–2032. Their leadership reflects the critical role of hospital-based cardiology departments in diagnosing, monitoring, and treating recurrent pericarditis, particularly among patients experiencing severe inflammatory episodes, frequent relapses, or treatment-resistant conditions. Access to advanced cardiac imaging, specialist consultations, hospitalization, and targeted anti-inflammatory therapies further strengthens hospitals’ position in recurrent pericarditis management.

Homecare Settings represent the fastest-growing end-user category in the Recurrent Pericarditis Market, accounting for 19% of the global market, valued at USD 132.04 million in 2025, and are projected to expand at a CAGR of 17.00% during 2026–2032. Growth is supported by the increasing preference for home-based disease management, regular symptom monitoring, and long-term treatment adherence. The shift from repeated hospital visits toward supervised homecare enables patients to manage recurring inflammatory episodes through prescribed therapies, lifestyle adjustments, and continuous medical follow-up.

 

By Geography: North America Leads While Asia-Pacific Records the Fastest Expansion

North America dominates the global Recurrent Pericarditis Market with a 48% share, equivalent to USD 333.57 million in 2025, and is projected to expand at a CAGR of 14.00% during 2026–2032. The region has witnessed a significant transformation in recurrent pericarditis management, supported by advanced cardiac imaging, improved diagnostic protocols, and growing adoption of targeted anti-inflammatory therapies. Wider clinical use of interleukin-1 inhibitors, particularly rilonacept, alongside specialized cardiovascular care and structured treatment guidelines, continues to strengthen therapeutic adoption across the United States and Canada.

Asia-Pacific holds a 16% share, representing USD 111.19 million in 2025 revenue, and is projected to register the fastest regional CAGR of 20.00% during 2026–2032. Expansion opportunities are associated with improving cardiovascular diagnostic capabilities, specialist treatment availability, and wider recognition of recurrent inflammatory cardiac conditions. China, Japan, India, and South Korea represent important potential markets for advanced therapies as cardiovascular specialty infrastructure and pharmaceutical access develop.

 

Which FDA-Approved Drugs and Emerging Pipeline Therapies Are Transforming the Recurrent Pericarditis Market?

FDA-Approved Drugs

ARCALYST (Rilonacept) – Kiniksa Pharmaceuticals

ARCALYST (rilonacept) is the only FDA-approved treatment specifically indicated for recurrent pericarditis, including reducing recurrence risk in adults and pediatric patients aged 12 years and older. Approved on March 18, 2021, rilonacept is a dual IL-1α and IL-1β inhibitor administered through weekly subcutaneous injections. The Phase III RHAPSODY trial demonstrated recurrence in 7% of rilonacept-treated patients versus 74% receiving placebo during randomized withdrawal. Its clinical effectiveness has established IL-1 inhibition as an important treatment strategy for recurrent inflammatory episodes, supporting specialty biologic prescribing and long-term disease management.

Emerging Pipeline Drugs and Investigational Therapies

1. KPL-387

KPL-387 is an investigational IL-1-targeted therapy being evaluated for recurrent pericarditis. Its clinical program aims to provide sustained suppression of inflammatory signaling and assess treatment efficacy, safety, and administration requirements. The ongoing Phase II/III program represents an opportunity for Kiniksa to expand its recurrent pericarditis portfolio beyond rilonacept.

2. CardiolRx (Cannabidiol Oral Solution) – Cardiol Therapeutics (Phase III)

CardiolRx is an investigational oral anti-inflammatory formulation designed to influence inflammatory pathways, including NLRP3 inflammasome activity. The Phase III MAVERIC trial is assessing its ability to prevent pericarditis recurrence in adults. CardiolRx has received FDA Orphan Drug Designation for pericarditis, and its oral administration could provide an alternative to injectable biologics if clinical efficacy and regulatory approval are established.

3. Goflikicept (RPH-104)

Goflikicept is a dual IL-1α/IL-1β inhibitor investigated for controlling recurrent pericardial inflammation. Clinical development has included Phase II/III evaluation in Russia. Its mechanism targets cytokines responsible for inflammatory recurrence, offering a potential biologic treatment option for patients with difficult-to-control disease.

4. VTX2735 – Oral NLRP3 Inflammasome Inhibitor (Phase II)

VTX2735 is an investigational oral therapy targeting the NLRP3 inflammasome, an upstream regulator of inflammatory cytokine activation. Phase II clinical evaluation in recurrent pericarditis is exploring its potential to reduce inflammatory activity. Its oral formulation could offer a differentiated approach to long-term disease management if clinical studies demonstrate suitable effectiveness and safety.

5. Canakinumab (ILARIS)

Canakinumab is a monoclonal antibody selectively targeting IL-1β. Although approved for other inflammatory diseases, its use in recurrent pericarditis remains investigational or off-label. Clinical evidence has explored its potential in selected patients with persistent or refractory inflammation. Its selective mechanism may offer an alternative to dual IL-1 inhibition, although recurrent pericarditis-specific evidence remains limited

 

Which Leading Pharmaceutical Companies Are Advancing Targeted Therapies in the Recurrent Pericarditis Market?

Kiniksa Pharmaceuticals – Leading Company in FDA-Approved IL-1 Inhibitor Therapy

Kiniksa Pharmaceuticals holds a leading commercial position in the Recurrent Pericarditis Market through ARCALYST (rilonacept), the first and only FDA-approved therapy specifically indicated for recurrent pericarditis. Approved on March 18, 2021, ARCALYST uses dual IL-1α and IL-1β inhibition to control recurrent pericardial inflammation in patients aged 12 years and older. In the pivotal Phase III RHAPSODY trial, involving 86 randomized patients, recurrence occurred in 7% of rilonacept-treated patients compared with 74% receiving placebo. Its once-weekly subcutaneous administration strengthens Kiniksa's commercial position in targeted biologics, while the investigational KPL-387 program supports further development of IL-1-directed treatment.

Cardiol Therapeutics Inc. – Leading Emerging Developer of Oral Anti-Inflammatory Therapy

Cardiol Therapeutics is a prominent emerging developer of targeted therapies for recurrent pericarditis through CardiolRx, an investigational oral cannabidiol formulation. The therapy is being investigated for its ability to regulate inflammatory pathways associated with recurrent pericardial episodes. CardiolRx received FDA Orphan Drug Designation for pericarditis, while its clinical development includes the Phase III MAVERIC program, evaluating recurrence prevention. Its oral formulation offers potential differentiation from injectable IL-1 inhibitors, creating opportunities for convenient long-term treatment and steroid-sparing disease management, subject to successful clinical and regulatory outcomes.

Other Key Companies and Their Market Roles

• Novartis AG: Contributes through ILARIS (canakinumab), a selective IL-1β monoclonal antibody investigated for difficult-to-treat recurrent pericarditis, although its use for this indication remains off-label.

• R-Pharm Group: Advances goflikicept (RPH-104), an investigational dual IL-1α/IL-1β inhibitor designed to control recurring inflammatory episodes and potentially reduce corticosteroid dependence.

 

Analyst Commentary: How Will IL-1 Therapies and Oral Innovation Reshape Long-Term Treatment?

The Recurrent Pericarditis Market is entering a new phase of therapeutic innovation, driven by growing clinical emphasis on preventing inflammatory relapses rather than managing individual episodes. The shift toward IL-1 inhibition, steroid-sparing therapies, and oral NLRP3 inflammasome inhibitors is creating opportunities for more precise disease management. Improved identification of autoinflammatory mechanisms, earlier specialist intervention, and convenient long-term treatment options are expected to strengthen clinical outcomes and accelerate the adoption of targeted therapies.

 

Recurrent Pericarditis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 694.94 Million
Revenue Forecast in 2032	USD 1.83 Billion
Overall Growth Rate	CAGR of 14.81% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026 – 2032)
Segmentation	By Treatment Type, By Disease Etiology, By Route of Administration, By Distribution Channel, By End User, By Geography
By Treatment Type	NSAIDs, Colchicine, Corticosteroids, IL-1 Inhibitors, Immunosuppressants
By Disease Etiology	Idiopathic Recurrent Pericarditis, Autoimmune-Associated Recurrent Pericarditis, Post-Cardiac Injury Recurrent Pericarditis, Infectious Recurrent Pericarditis
By Route of Administration	Oral Administration, Subcutaneous Administration, Intravenous Administration
By Distribution Channel	Hospital Pharmacies, Retail Pharmacies, Specialty Pharmacies, Online Pharmacies
By End User	Hospitals, Specialty Clinics, Homecare Settings
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, China, Japan, South Korea, India, Brazil, Mexico, Saudi Arabia, UAE, South Africa
Market Drivers	Increasing adoption of IL-1 inhibitors, long-term recurrence-prevention treatment requirements, expansion of specialist pericardial disease services, specialty pharmacy support for biologic access, development of targeted oral therapies
Customization Option	Available upon request